Clinical Trial Update: Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) [Phase 3]

View source ↗

Summary

Phase 3 trial EYEGUARD-B evaluating gevokizumab for Behçet's disease-related uveitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease

Drugs mentioned

• Gevokizumab (gevokizumab)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Behcet's Uveitis | Phase 3 | Status: TERMINATED